TOKYO, Japan, 9 September 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the interim analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate ( “lenvatinib”) will be presented...
Archives: News
PRISM BioLab opens a business office in Tokyo
We are pleased to announce the establishment of PRISM BioLab Co., Ltd. Tokyo office. The office was officially opened on September 2, 2024 and will serve as a base for our business and administrative functions, for enhanced communications with our investors and partners, and to enable more effective business decisions. We sincerely appreciate the continued...
Announcement of Initial Listing on Tokyo Stock Exchange Growth Market
PRISM BioLab Corporation is pleased to announce its initial listing on the Tokyo Stock Exchange Growth Market today. We would like to take this opportunity to express our sincere gratitude to all our stakeholders for their unwavering support and cooperation. For more details regarding our new listing, please visit the Tokyo Stock Exchange website. https://www.jpx.co.jp/listing/stocks/new/index.html...
Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange
PRISM BioLab is pleased to announce that the Tokyo Stock Exchange today approved the initial listing of our shares on the Growth Market of the Tokyo Stock Exchange. Read Full Press Release-Japanese Text Only
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
TOKYO, Japan, 25 Apr 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. . Read Full Press Release
Announcement of setting the record date for stock split
Announcement of setting the record date for stock split(pdf)
PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions
TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of...
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company. Read Full Press Release
Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein–Protein Interaction between CTLA-4 and B7-1
Pharmaceuticals 2022, 15(12), 1506
Tsuihiji, Kumiko; Honda, Eiji; Kojoh, Kanehisa; Katoh, Shizue; Taguri, Tomonori; Yoshimori, Atsushi; Takashima, Hajime
Development of low-molecular-weight compounds targeting the cancer-associated KLF5 transcription factor
ACS Medicinal Chemistry Letters, 13(4), 687-694 (2022)
Nakaya, Takeo; Aizawa, Kenichi; Taguchi, Yuki; Tsuji, Kentaro; Sekine, Sachi; Murakami, Kazuhiro; Kasai, Masaji; Nakano, Hirofumi; Kondoh, Yasumitsu; Dan, Shingo; Yoshimori, Atsushi; Kouji, Hiroyuki; Takehara, Dai; Suzuki, Toru; Osada, Hiroyuki; Marata, Masayuki; Tanaka, Akira; Nagai, Ryozo